Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$22.17 - $51.8 $1.03 Million - $2.41 Million
46,615 Added 508.51%
55,782 $2.88 Million
Q2 2022

Aug 15, 2022

BUY
$15.36 - $27.51 $140,805 - $252,184
9,167 New
9,167 $227,000
Q2 2021

Aug 16, 2021

SELL
$9.59 - $50.88 $312,413 - $1.66 Million
-32,577 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$49.53 - $68.4 $799,909 - $1.1 Million
16,150 Added 98.31%
32,577 $1.67 Million
Q4 2020

Feb 12, 2021

BUY
$47.25 - $65.16 $70,166 - $96,762
1,485 Added 9.94%
16,427 $1.02 Million
Q3 2020

Nov 16, 2020

BUY
$46.35 - $61.69 $692,561 - $921,771
14,942 New
14,942 $819,000
Q3 2019

Nov 14, 2019

SELL
$6.47 - $8.96 $719,638 - $996,593
-111,227 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$8.31 - $14.85 $1.25 Million - $2.23 Million
-150,169 Reduced 57.45%
111,227 $1.03 Million
Q1 2019

May 15, 2019

SELL
$10.01 - $13.89 $31,031 - $43,059
-3,100 Reduced 1.17%
261,396 $3.63 Million
Q4 2018

Feb 14, 2019

BUY
$9.15 - $12.26 $1.19 Million - $1.6 Million
130,109 Added 96.82%
264,496 $2.89 Million
Q3 2018

Nov 14, 2018

BUY
$10.49 - $13.72 $672,052 - $878,985
64,066 Added 91.11%
134,387 $1.7 Million
Q2 2018

Aug 14, 2018

BUY
$10.62 - $13.98 $746,809 - $983,087
70,321 New
70,321 $926,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.